Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 342-352

  Cea, Michele ^a,b   Cagnetta, Antonia ^a,b   Cirmena, Gabriella ^c   Garuti, Anna ^c   Rocco, Ilaria ^c   Palermo, Claudia ^c   Pierri, Ivana ^b   Reverberi, Daniele ^c   Nencioni, Alessio ^c   Ballestrero, Alberto ^c   Gobbi, Marco ^b   Carella, Angelo Michele ^b   Patrone, Franco ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Department of Hematology and Oncology ^*  (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic myeloid leukemia; Leukemic stem cell; Molecular monitoring; Resistance to treatment

Indexed keywords

BCR ABL PROTEIN; MESSENGER RNA; PROTEIN PATCHED 1; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA RELAPSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HEDGEHOG PROTEINS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; RECURRENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872045017     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.708752     Document Type: Article

References (40)

1. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
2. Deininger MW, Goldman JM, Melo JV. Themolecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343-3356.
3. Goldman JM, Melo JV. Chronic myeloid leukemia-a dvances in biology and new approaches to treatment. NEngl JMed 2003; 349: 1451-1464.
4. Foo J, Drummond MW, Clarkson B, et al. Eradication of chronic myeloid leukemia stem cells: anovel mathematical model predicts no therapeutic benefitof adding G-CSF to imatinib. PLoS Comput Biol 2009; 5: e1000503.
5. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005; 15: 494-501.
7. Lucas CM, Wang L, Austin GM, et al. Apopulation study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963-1966.
8. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. JClin Oncol 2008; 26: 3358-3363.
9. Peggs K, Mackinnon S. Imatinib mesylate-t he new gold standard for treatment of chronic myeloid leukemia. NEngl JMed 2003; 348: 1048-1050.
10. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
11. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
12. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010; 101: 1577-1581.
13. Hu Y, Chen Y, Douglas L, et al. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009; 23: 109-116.
14. Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010; 466: 765-768.
15. Hidalgo M, Maitra A. Thehedgehog pathway and pancreatic cancer. NEngl JMed 2009; 361: 2094-2096.
16. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in amouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
17. Rohatgi R, Scott MP. Patching the gaps in Hedgehog signalling. Nat Cell Biol 2007; 9: 1005-1009.
18. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on atheme by sonic hedgehog. Nat Rev Genet 2006; 7: 841-850.
19. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008; 14: 238-249.
20. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458: 776-779.
21. Duman-Scheel M, Weng L, Xin S, et al. Hedgehog regulates cell growth and proliferation by inducing Cyclin Dand Cyclin E. Nature 2002; 417: 299-304.
22. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 2004; 104: 4245-4251.
23. Ballestrero A, Cirmena G, Dominietto A, et al. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, aretrospective analysis in allogeneic bone marrow recipients. Int JLab Hematol 2010; 32: 387-391.
24. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
25. Bouzar AB, Boxus M, Defoiche J, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br JHaematol 2009; 144: 41-52.
26. Mason KD, Khaw SL, Rayeroux KC, et al. TheBH3 mimetic compound, ABT-737, synergizes with arange of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034-2041.
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
28. Deguchi Y, Kimura S, Ashihara E, et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008; 32: 980-983.
29. Kim J, Tang JY, Gong R, et al. Itraconazole, acommonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17: 388-399.
30. Kim J, Lee JJ, Gardner D, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci USA 2010; 107: 13432-13437.
31. Long B, Zhu H, Zhu C, et al. Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients. JExp Clin Cancer Res 2011; 30: 8.
32. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010; 29: 6314-6322.
33. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. JClin Oncol 2003; 21: 1637-1647.
34. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to acure for chronic myeloid leukemia. Blood 2007; 110: 2242-2249.
35. Hasford J, Ansari H, Pfirrmann M, et al. Analysis and validation of prognostic factors for CML. German CML Study Group. Bone Marrow Transplant 1996; 17(Suppl. 3): S49-S54.
36. Hehlmann R, Ansari H, Hasford J, et al. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal'sindex and anew score. German chronic myeloid leukaemia (CML)-Study Group. Br JHaematol 1997; 97: 76-85.
37. Mohty M, Yong AS, Szydlo RM, et al. Thepolycomb group BMI1 gene is amolecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-383.
38. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006; 81: 973-988.
39. Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010; 101: 1577-1581.
40. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program 2009: 453-460.